STAT5A and chronic myelogenous leukemia, BCR-ABL1 positive: Besides these potential mechanisms, the capacity of 17f to restore the sensitivity of resistant CML or AML cells to IM or Ara-C suggests that inhibitors targeting STAT5 expression would also benefit AML or CML patients who have developed resistance to chemotherapy.